Obiltoxaximab

Identification

Summary

Obiltoxaximab is a monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.

Brand Names
Anthim
Generic Name
Obiltoxaximab
DrugBank Accession Number
DB05336
Background

Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
148000.0 Da
Sequences
Not Available
Synonyms
  • Obiltoxaximab
External IDs
  • ETI-204

Pharmacology

Indication

Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Obiltoxaximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Obiltoxaximab.
AducanumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab.
AlirocumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Amivantamab.
AnsuvimabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obiltoxaximab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AnthimSolution100 mg / mLIntravenousElusys Therapeutics IncNot applicableNot applicableCanada flag
AnthimSolution100 mg/1mLIntravenousElusys Therapeutics, Inc.2016-03-18Not applicableUS flag
Obiltoxaximab SflInjection, solution, concentrate100 mg/mlIntravenousSfl Pharmaceuticals Deutschland Gmb H2020-12-23Not applicableEU flag

Categories

ATC Codes
J06BB22 — Obiltoxaximab
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
29Z5DNL48C
CAS number
1351337-07-9

References

General References
  1. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun. 2005 Feb;73(2):795-802. [Article]
PubChem Substance
347910089
RxNav
1746906
Wikipedia
Obiltoxaximab
FDA label
Download (315 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentAnthrax / Bacterial Infections1
1CompletedOtherInhaled anthrax caused by Bacillus anthracis4
1CompletedTreatmentAnthrax1
1CompletedTreatmentBacillus Anthracis (Anthrax)1
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous100 mg/1mL
SolutionIntravenous100 mg / mL
Injection, solution, concentrateIntravenous100 mg/ml
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created on November 18, 2007 18:23 / Updated on April 30, 2021 13:06